



US011207332B2

(12) **United States Patent**  
**Ajani et al.**(10) **Patent No.: US 11,207,332 B2**  
(45) **Date of Patent: \*Dec. 28, 2021**(54) **ENZYMATIC PROCESS FOR OBTAINING 17 $\alpha$ -MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11-DEHYDRODERIVATIVES**

- (71) Applicant: **Cassiopea S.P.A.**, Lainate (IT)
- (72) Inventors: **Mauro Ajani**, Lainate (IT); **Luigi Moro**, Caiate (IT)
- (73) Assignee: **Cassiopea S.P.A.**, Lainate (IT)
- (\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 119 days.  
This patent is subject to a terminal disclaimer.

(21) Appl. No.: **16/686,738**(22) Filed: **Nov. 18, 2019**(65) **Prior Publication Data**

US 2020/0155572 A1 May 21, 2020

**Related U.S. Application Data**

- (60) Continuation of application No. 16/195,083, filed on Nov. 19, 2018, now Pat. No. 10,716,796, which is a continuation of application No. 15/211,087, filed on Jul. 15, 2016, now Pat. No. 10,166,245, which is a division of application No. 14/073,928, filed on Nov. 7, 2013, now Pat. No. 9,433,628, which is a division of application No. 12/671,932, filed as application No. PCT/EP2008/059702 on Jul. 24, 2008, now Pat. No. 8,785,427.

(30) **Foreign Application Priority Data**

Aug. 3, 2007 (IT) ..... MI2007A001616

(51) **Int. Cl.**

- A61K 31/573** (2006.01)  
**C07J 5/00** (2006.01)  
**C07J 7/00** (2006.01)  
**A61K 9/00** (2006.01)  
**A61K 47/10** (2017.01)  
**A61K 47/14** (2017.01)  
**A61K 9/06** (2006.01)  
**A61K 47/06** (2006.01)  
**A61K 47/26** (2006.01)  
**A61K 47/44** (2017.01)  
**C12P 33/00** (2006.01)

(52) **U.S. Cl.**

- CPC ..... **A61K 31/573** (2013.01); **A61K 9/0014** (2013.01); **A61K 9/06** (2013.01); **A61K 47/06** (2013.01); **A61K 47/10** (2013.01); **A61K 47/14** (2013.01); **A61K 47/26** (2013.01); **A61K 47/44** (2013.01); **C07J 5/0053** (2013.01); **C07J 7/008** (2013.01); **C07B 2200/13** (2013.01); **C12P 33/005** (2013.01)

(58) **Field of Classification Search**

- CPC ..... A61K 31/573; A61P 17/00; A61P 17/08; A61P 17/10; A61P 17/14; C07J 5/0053; C07J 7/008; C07B 2200/13

See application file for complete search history.

(56)

**References Cited**

## U.S. PATENT DOCUMENTS

- 2,985,650 A 5/1961 Batres et al.  
3,152,154 A 10/1964 Ercoli et al.  
3,431,173 A 3/1969 van der Waard et al.  
3,530,038 A 9/1970 de Flines et al.  
3,733,318 A 5/1973 Marx M.  
3,780,177 A 12/1973 Ercoli et al.  
4,645,763 A 2/1987 Annen et al.  
4,670,427 A 6/1987 Annen et al.  
5,264,428 A 11/1993 Streber  
8,785,427 B2 7/2014 Ajani et al.  
9,433,628 B2 9/2016 Ajani et al.  
9,486,458 B2 11/2016 Ajani et al.  
10,159,682 B2 12/2018 Ajani et al.  
10,166,245 B2 1/2019 Ajani et al.  
2004/0138187 A1 7/2004 Reading et al.  
2005/0227994 A1 10/2005 Gemba et al.  
2011/0092472 A1 4/2011 Ajani et al.  
2012/0149671 A1 6/2012 Ajani et al.  
2014/0079686 A1 3/2014 Barman et al.  
2014/0154306 A1 6/2014 Ajani et al.  
2014/0179654 A1 6/2014 Ajani et al.  
2016/0051566 A1 2/2016 Ajani et al.  
2016/0324873 A1 11/2016 Ajani et al.  
2019/0282589 A1 9/2019 Longo  
2019/0374553 A1 12/2019 Longo

## FOREIGN PATENT DOCUMENTS

- AU 729928 B2 2/2001  
DE 196 53 730 A1 6/1998  
GB 791771 3/1958

(Continued)

## OTHER PUBLICATIONS

- Annen, K., et al., "17-Pivalate in der Pregnanreihe," Liebigs Ann. Chem:705-711, Wiley-VCH Verlag GmbH & Co. KGaA, Germany (1983).  
Baldessari et al., "86. Lipase-Catalysed Regioselective Deacetylation of Androstan Derivatives," Helvetica Chimica Acta 79 (1996).  
Belieu, R.M., "Mastodynia," Obstetrics and Gynecology Clinics of North America 21(3):461-477, W.B. Saunders Company, United States (1994).

(Continued)

Primary Examiner — Barbara P Radio

(74) Attorney, Agent, or Firm — Sterne, Kessler, Goldstein &amp; Fox P.L.L.C.; Matthew S. Bodenstein

(57)

**ABSTRACT**

The present invention refers to a new enzymatic process for obtaining 17 $\alpha$ -monoesters of cortexolone and/or its 9,11-dehydroderivatives starting from the corresponding 17 $\alpha$ ,21-diester which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to new crystalline forms of cortexolone-17 $\alpha$ -propionate and 9,11-dehydro-cortexolone 17 $\alpha$ -butanoate.

(56)

**References Cited****FOREIGN PATENT DOCUMENTS**

IT	MI20132157 A1	6/2015
JP	52010489	1/1977
JP	59-106500 A	6/1984
JP	60-161998 A	8/1985
JP	2004-530703 A	10/2004
JP	2005-504762	2/2005
JP	2005-539016 A	12/2005
WO	WO 88/09337 A1	12/1988
WO	WO 02/094843 A1	11/2002
WO	WO 03/014141 A1	2/2003
WO	WO 03/080042 A1	10/2003
WO	WO 2004/014935 A1	2/2004
WO	WO 2004/060347 A2	7/2004
WO	WO 2005/004917 A2	1/2005
WO	WO 2006/121097 A1	11/2006
WO	WO 2007/014927 A2	2/2007
WO	WO 2007/031349 A1	3/2007

**OTHER PUBLICATIONS**

- Biollaz, von M. and Kalvoda, J., "263. Reaktionen von Steroiden mit Dialkylaminoschweif trifluoriden. I. 11 $\beta$ -Hydroxysteroids," *Helvetica Chimica Acta* 60(8):2703-2710, Schweizerische Chemische Gesellschaft, Switzerland (1977).
- Bruttomesso, et al., "Lipase-catalysed deacetylation of androstanone and pregnane derivatives: influence of ring D substitution," *Journal of Molecular Catalysis B: Enzymatic* 29:149-153 (2004).
- Caira, M.R., "Crystalline Polymorphism of Organic Compounds," in *Topics in Current Chemistry*, vol. 198, de Meijere, A., et al., Eds., pp. 164-208, Springer-Verlag, Germany (1998).
- Celasco, et al., "Biological Profile of Cortexolone 17 $\mu$ -Propionate (CB-03-01), a New Topical and Peripherally Selective Androgen Antagonist," *Arzneim. Forsch./Drug Res* 54(12):881-886 (2004).
- Cheung, et al., "Resistance to enzymic hydrolysis as a parameter in drug potency," *International Journal of Pharmaceuticals* 27:325-333 (1985).
- Ferraboschi, et al., "Lipase-catalyzed preparation of corticosteroid 17 $\mu$ -esters endowed with antiandrogenic activity," *Tetrahedron Letters* 49:4610-4612 (2008).
- Ford, J.L. and Timmins, P., Eds., "Ch. 6 Thermal analysis in the characterization of pharmaceutical solids," in *Pharmaceutical Thermal Analysis: Techniques and Applications*, pp. 139-140, Ellis Horwood Limited, England (1989).
- Franssen, et al., "Enzymatic alcoholysis of alkoxy methyl alkanoates: a possible approach for the kinetic resolution of tertiary alcohols," *Tetrahedron Letters* 39:8345-8348 (2004).
- Gardi, R., et al., "52. Derivati di condensazione nella catena laterale di corticosteroidi.—Nota III. Preparazione e reazioni dei 17-monesteri," *Gazz. Chim. It.* 93:431-450, Palermo, Italy (1963).
- Gardi, R., et al., "Corticosteroid 17 $\alpha$ -Monoesters from 17 $\alpha$ ,21-Cyclic Orthoesters," *Tetrahedron Letters* 13:448-451, Pergamon Press Ltd., Great Britain (1961).
- Hilfiker, R., Ed., "Characterization of Polymorphic Systems Using Thermal Analysis," in *Polymorphisms in the Pharmaceutical Industry*, pp. 46-48, Wiley-VCH Verlag GmbH & Co. KGaA, Germany (2006).
- Meriggiola, M.C. and Pelusi, G., "Advances in male hormonal contraception," *Expert Opin. Investig. Drugs* 15(4):389-397, Ashley Publications, England (2006).
- Misaki, et al., "Enzymic hydrolysis of hydrocoristone diesters in skin," *Yakuzaigaku* No. 42(2), Abstract. CAPLUS Chemical Abstract Service Database Accession No., 1982:575431.
- Morrison, R.T. and Boyd, R.N., Eds., "Chap. 20 Functional Derivatives of Carboxylic Acids," in *Organic Chemistry*, Sixth Edition, pp. 764-766, Prentice-Hall, Inc., Englewood Cliffs, New Jersey, United States (1992).
- Schinzer, W.C., et al., "Characterization and Interconversion of Polymorphs of Premafloxacin, a New Quinolone Antibiotic," *Journal of Pharmaceutical Sciences* 86(12):1426-1431, American Chemical Society and American Pharmaceutical Association, United States (1997).
- Tuladhar, M.D., et al., "Thermal behaviour and dissolution properties of phenylbutazone polymorphs," *J. Pharm. Pharmacol.* 35:208-214, Pharmaceutical Society of Great Britain, England (1983).
- Turner, R.B., "Acylation of 17-Hydroxy-20-ketosteroids," *J. Am. Chem. Soc.* 75:3489-3492, American Chemical Society, United States (1953).
- Voigt, W. and Hsia, S.L., "The Antiandrogenic Action of 4-Androsten-3-one-17 $\beta$ -Carboxylic Acid and Its Methyl Ester on Hamster Flank Organ," *Endocrinology* 92(4):1216-1222, Endocrine Society, United States (1973).
- Japanese Office Action for Application No. 2010-518628 dated Feb. 8, 2013.
- Non-Final Office Action, dated Sep. 25, 2006 for U.S. Appl. No. 10/486,386, filed Sep. 16, 2004.
- Final Office Action, dated Apr. 13, 2007 for U.S. Appl. No. 10/486,386, filed Sep. 16, 2004.
- Non-Final Office Action, dated Sep. 7, 2007 for U.S. Appl. No. 10/486,386, filed Sep. 16, 2004.
- Final Office Action, dated Mar. 21, 2008 for U.S. Appl. No. 10/486,386, filed Sep. 16, 2004.
- Non-Final Office Action, dated Jul. 10, 2008 for U.S. Appl. No. 10/486,386, filed Sep. 16, 2004.
- Final Office Action, dated Feb. 27, 2009 for U.S. Appl. No. 10/486,386, filed Sep. 16, 2004.
- Non-Final Office Action, dated Jul. 13, 2011 for U.S. Appl. No. 12/457,870, filed Jun. 24, 2009.
- Non-Final Office Action, dated Apr. 24, 2014 for U.S. Appl. No. 14/103,707, filed Dec. 11, 2013.
- Byrn, S., et al., "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations," *Pharmaceutical Research* 12(7):945-954, Plenum Publishing Company, United States (1995).
- Notice of Allowance, dated Sep. 23, 2015 for U.S. Appl. No. 14/474,765, Ajani, M., et al., filed Sep. 2, 2014.
- Bavin, M., "Polymorphism in process development, (crystal structure transformations)" in Chemistry and Industry, accessed at <https://www.highbeam.com/doc/1G1-7901419.html>, accessed on Nov. 17, 2016, Society of Chemical Industry, United States, 5 pages (1989).
- Office Action dated Nov. 28, 2017, in U.S. Appl. No. 15/211,087, inventor Ajani, M. et al., filed Jul. 15, 2016, 6 pages.
- Office Action dated May 10, 2018, in U.S. Appl. No. 15/211,087, inventor Ajani, M. et al., filed Jul. 15, 2016, 8 pages.
- Office Action dated Nov. 20, 2017, in U.S. Appl. No. 15/211,094, inventor Ajani, M. et al., filed Jul. 15, 2016, 6 pages.
- Office Action dated May 3, 2018, in U.S. Appl. No. 15/211,094, inventor Ajani, M. et al., filed Jul. 15, 2016, 7 pages.
- Clinical trials data published on Oct. 31, 2014, retrieved from [https://clinicaltrials.gov/ct2/history/NCT02279823?V\\_1=View#studypagetop](https://clinicaltrials.gov/ct2/history/NCT02279823?V_1=View#studypagetop), 7 pages.
- Cosmo Pharmaceuticals S.p.A. Reports Exciting Results in P.O.C. Alopecia Study, published on Oct. 6, 2010, retrieved from <https://www.biospace.com/article/releases/cosmo-pharmaceuticals-s-p-a-reports-exciting-results-in-p-o-c-alopelia-study/>, 4 pages.
- Blagden, N., et al., "Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates," *Advanced Drug Delivery Reviews* 59:617-630, Elsevier B.V., Netherlands (2007).
- Morissette, S. L., et al., "High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids," *Advanced Drug Delivery Reviews* 56:275-300, Elsevier B.V., Netherlands (2004).
- Vishweshwar, P., et al., "Pharmaceutical Co-Crystals," *Journal of Pharmaceutical Sciences* 95(3):499-516, Wiley-Liss, Inc. and the American Pharmacists Association, United States (2006).
- Khankari, R. K., et al., "Pharmaceutical hydrates," *Thermochimica Acta* 248:61-29, Elsevier B.V., Netherlands (1995).
- Piacquadio, D., et al., "Safety and steady state pharmacokinetics of cortexolone 17 $\alpha$ -propionate (cb-03-01) 1% cream in adult subjects with acne vulgaris," *J. Am. Acad. Dermatol.* 70:AB10, Abstract No. P8172, Journal of the American Academy of Dermatology (2014).

(56)

**References Cited**

OTHER PUBLICATIONS

Non-Final Office Action dated Jul. 25, 2019 for U.S. Appl. No. 16/400,262, filed May 1, 2019.  
Third Party Submission dated Oct. 17, 2019, mailed Oct. 22, 2019 for U.S. Appl. No. 16/400,262, filed May 1, 2019 (21 pages).  
Non-Final Office Action dated Oct. 2, 2019 for U.S. Appl. No. 16/195,083, filed Nov. 19, 2018.  
Final Office Action dated Mar. 17, 2020 for U.S. Appl. No. 16/195,083, filed Nov. 19, 2018.

## CORTEXOLONE 17 ALPHA-PROPIONATE CB-03-01 METHILTERBUTYLETHER

Smoothing






Fig. 1

## CORTEXOLONE, 17 ALPHA-PROPIONATE CB-03-01 METHILTERBUTYLETHER



1) Heat from 50.00° to 150.00° C/min.


Fig. 2




Description: Cortexolone 17 alpha-propionate CB-03-01 methylterbutylerher  
Comments: Tablet in KBr without vacuum

Fig. 3

CORTEXOLONE 17 ALPHA-PROPIONATE CB-03-01 DIISOPROPYL ETHER (GROUND BY MORTAR)


**FIG. 4**

## CORTEXOLONE 17 ALPHA-PROPIONATE CB-03-01 DIISOPROPYLETHER (GROUND BY MORTAR)



1) Heat from 50.00° to 150.00°C at 10.00°C/min

Fig. 5



Description: Cortexolone 17 alpha-propionate CB-03-01 diisopropylether

Fig. 6




CORTEXOLONE 17 ALPHA-PROPIONATE CB-03-01CH<sub>2</sub>Cl<sub>2</sub>HEXANE

Fig. 7

CORTEXOLONE 17 ALPHA-PROPIONATE CB-03-01CH<sub>2</sub>Cl<sub>2</sub>HEXANE

1) Heat from 50.00° to 150.00°C at 10.00°C/min

Fig. 8



Description: Cortexolone 17 alpha-propionate CB-03-01 CH<sub>2</sub>Cl<sub>2</sub>\_Hexane  
Comments: Tablet in KBr without vacuum

Fig. 9

CORTEXOLONE 17 ALPHA-PROPIONATE CB-03-01 ACETONE-HEXANE






Fig. 10

## CORTEXOLONE 17 ALPHA-PROPIONATE CB-03-01 ACETONE-HEXANE



1) Heat from 50.00° to 150.00°C at 5.00°C/min

**FIG. 11**



Description: Cortexolone 7 alpha-Droponate batch CB-03-01




CORTEXOLONE 17 ALPHA-PROPIONATE EtOH/H<sub>2</sub>O (1:2)

Fig. 13

CORTEXOLONE 17 ALPHA-PROPIONATE EtOH/H<sub>2</sub>O (1:2)

1) Heat from 50.00° to 150.00°C at 10.00°C/min

**FIG. 14**



Description: Cortexolone 7 alpha-propionate EtOH-H<sub>2</sub>O TQ  
Comments: Tablet in KBr without vacuum dil 1:100 bk air

Fig. 15

## 9-DEHYDROCORTEXOLONE 17 ALPHA-BUTYRATE Methylterbutylether






Fig. 16



1) Heat from 50.00° to 150.00°C at 10.00°C/min

**FIG. 17**



Description: Methylterbutyl ether

Comments: Tablet in KBr without vacuum

Fig. 18

## 9-DEHYDROCORTEXOLONE 17 ALPHA-BUTYRATE Ether Disopropylate





Fig. 19

9-DEHYDROCORTEXOLONE 17 ALPHA-BUTYRATE Ether Diisopropilic



1) Heat from 50.00° to 150.00°C at 10.00°C/min

**FIG. 20**




Fig. 21



9-DEHYDROCORTEXOLONE 17 ALPHA-BUTYRATE CH<sub>2</sub>Cl<sub>2</sub>/HEXANE

Fig. 22

9-DEHYDROCORTEXOLONE 17 ALPHA-BUTYRATE CH<sub>2</sub>Cl<sub>2</sub>/HEXANE

1) Heat from 50.00° to 150.00°C at 10.00°C/min

Fig. 23




Fig. 24

9-DEHYDROCORTEXOLONE 17 ALPHA-BUTYRATE ACETONE/HEXANE





Fig. 25

## 9-DEHYDROCORTEXOLONE 17 ALPHA-BUTYRATE ACETONE/HEXANE



1) Heat from 50.00° to 350.00°C at 10.00°C/min

Fig. 26




Fig. 27

SPECTRUM DRX OF CORTEXOLONE 17 ALPHA-PROPIONATE INTO THE FORMULATION (CREAM)




Fig. 28


**1**
**ENZYMATIC PROCESS FOR OBTAINING 17 $\alpha$ -MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11-DEHYDRODERIVATIVES**

Cortexolone derivatives in which the hydroxyl group at position C-17 $\alpha$  is esterified with short chain aliphatic or aromatic acids, and the derivatives of the corresponding 9,11-dehydro derivative, are known to have an antiandrogenic effect.

EP1421099 describes cortexolone 17 $\alpha$ -propionate and 9,11-dehydro-cortexolone-17 $\alpha$ -butanoate regarding a high antiandrogenic biological activity demonstrated both "in vitro" and "in vivo" on the animal.

A method for obtaining the above mentioned derivatives is described by Gardi et al. (Gazz. Chim. It, 63, 43 1,1963) and in the U.S. Pat. No. 3,152,154 providing for the transformation of cortexolone, or transformation of 9,11-dehydrocortexolone, in the intermediate orthoester using orthoesters available in the market as a mixture of aprotic solvents such as cyclohexane and DMF, in presence of acid catalysis (ex. PTSA.H<sub>2</sub>O). The intermediate orthoester thus obtained can be used as is or upon purification by suspension in a solvent capable of solubilizing impurities, preferably in alcohols. The subsequent hydrolysis in a hydroalcoholic solution, buffered to pH 4-5 preferably in acetate buffer, provides the desired monoester.

Such synthesis is indicated in the diagram 1 below.

**2**


448, 1961). The instability is above all due to the secondary reaction of migration of the esterifying acyl group from position 17 to position 21.

It is thus known that in order to obtain the above mentioned monoesters with a chemical purity in such a manner to be able to proceed to the biological tests, it is necessary to use, at the end of the synthesis, a purification process which is generally performed by means of column chromatography.

Furthermore, U.S. Pat. No. 3,152,154 describes how the hydrolysis of the diester in a basic environment is not convenient due to the formation of a mixture of 17 $\alpha$ ,21-diol, of 17- and 21-monoesters, alongside the initial non-reacted product.

Now, it has been surprisingly discovered that an alcoholysis reaction using a lipase from *Candida* as a biocatalyst can be usefully applied during the preparation of 17 $\alpha$  monoesters of cortexolone, or its 9,11-dehydroderivatives.

As a matter of fact, it has been discovered that such enzymatic alcoholysis of the 17,21-diester of the cortexolone, or of its derivative 9,11-dehydro, selectively occurs in position 21 moving to the corresponding monoester in position 17, as shown in diagram 2 below:




The chemoselectivity of the special enzymatic reaction in alcoholysis conditions, according to the present invention, opens new perspectives for preparation, at industrial level with higher yields, of 17 $\alpha$ -monoesters with respect to the methods already indicated in literature.


The diesters serving as a substrate for the reaction of the invention can be prepared according to the prior art, for example following the one described in B. Turner, (Journal of American Chemical Society, 75, 3489, 1953) which provides for the esterification of corticosteroids with a linear carboxylic acid in presence of its anhydride and PTSA monohydrate.

Therefore, an object of the present invention is a process for the preparation of 17 $\alpha$  monoesters of cortexolone, and its 9,11-dehydroderivatives, of formula I.

However, the monoesters thus obtained were, in the reaction conditions, unstable and, consequently hard to manipulate and isolate (R. Gardi et al Tetrahedron Letters,




wherein R is a linear or branched aliphatic or aromatic chain containing 1 to 10 carbon atoms, characterized in  
15  
that a compound of formula II



wherein R bears the same meaning indicated above,  
is reacted with a compound having the formula R'OH,  
wherein R' is a linear chain containing 1 to 10 carbon  
atoms, preferably a C<sub>1</sub>-C<sub>8</sub> alkyl, in presence of a lipase  
35 from *Candida*. According to the present invention R is  
preferably a C<sub>1</sub>-C<sub>4</sub> alkyl, even more preferably it is  
selected from among CH<sub>3</sub>, CH<sub>3</sub>CH<sub>2</sub>, CH<sub>3</sub>(CH<sub>2</sub>)<sub>2</sub> or  
CH<sub>3</sub>(CH<sub>2</sub>)<sub>3</sub>.

The dashed symbol in position 9,11 inside the abovementioned formulas I and II means that the double bond can be present (9,11-dehydroderivative) or not present in such position, as shown in the formulas indicated hereinafter



## BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a DRX spectrum of crystalline form I of cortexolone-17α-propionate.

FIG. 2 shows a DSC spectrum of crystalline form I of cortexolone-17α-propionate.

FIG. 3 shows an IR spectrum of crystalline form I of cortexolone-17α-propionate.

FIG. 4 shows a DRX spectrum of crystalline form II of cortexolone-17α-propionate.

FIG. 5 shows a DSC spectrum of crystalline form II of cortexolone-17α-propionate.

FIG. 6 shows an IR spectrum of crystalline form II of cortexolone-17α-propionate.

FIG. 7 shows a DRX spectrum of crystalline form III of cortexolone-17α-propionate.

FIG. 8 shows a DSC spectrum of crystalline form III of cortexolone-17α-propionate.

FIG. 9 shows an IR spectrum of crystalline form III of cortexolone-17α-propionate.

FIG. 10 shows a DRX spectrum of crystalline form III of cortexolone-17α-propionate.

FIG. 11 shows a DSC spectrum of crystalline form III of cortexolone-17α-propionate.

FIG. 12 shows an IR spectrum of crystalline form III of cortexolone-17α-propionate.

FIG. 13 shows a DRX spectrum of crystalline form III of cortexolone-17α-propionate.

FIG. 14 shows a DSC spectrum of crystalline form III of cortexolone-17α-propionate.

FIG. 15 shows an IR spectrum of crystalline form III of cortexolone-17α-propionate.

FIG. 16 shows a DRX spectrum of crystalline form I of cortexolone-17α-propionate.

FIG. 17 shows a DSC spectrum of crystalline form I of cortexolone-17α-propionate.

FIG. 18 shows an IR spectrum of crystalline form I of cortexolone-17α-propionate.

FIG. 19 shows a DRX spectrum of crystalline form I of cortexolone-17 $\alpha$ -propionate.

FIG. 20 shows a DSC spectrum of crystalline form I of cortexolone-17 $\alpha$ -propionate.

FIG. 21 shows an IR spectrum of crystalline form I of cortexolone-17 $\alpha$ -propionate.

FIG. 22 shows a DRX spectrum of crystalline form I of cortexolone-17 $\alpha$ -propionate.

FIG. 23 shows a DSC spectrum of crystalline form I of cortexolone-17 $\alpha$ -propionate.

FIG. 24 shows an IR spectrum of crystalline form I of cortexolone-17 $\alpha$ -propionate.

FIG. 25 shows a DRX spectrum of crystalline form I of cortexolone-17 $\alpha$ -propionate.

FIG. 26 shows a DSC spectrum of crystalline form I of cortexolone-17 $\alpha$ -propionate.

FIG. 27 shows an IR spectrum of crystalline form I of cortexolone-17 $\alpha$ -propionate.

FIG. 28 shows a DRX spectrum of cortexolone-17 $\alpha$ -propionate crystallized during the preparation of a cream formulation.

The lipase from *Candida* used to catalyze the process of the present invention is preferably selected between the lipase from *Candida cylindracea* (CCL) and lipase from *Candida antarctica* of type B (CALB).

Lipase from *Candida*, and in particular the ones from *Candida cylindracea* and *Candida antarctica* are proved to be capable of selectively hydrolyzing the ester function in position 21, contrary to the porcine pancreatic lipase (PPL) and to one from *Pseudomonas fluorescens* (PFL), which are proved to be almost inactive.

The amount of said enzyme, calculated with respect to the initial substrate, may vary depending on the type of enzyme used. In particular, said enzyme is preferably used in an amount in the range of 100 to 1,000,000 U/mmol; more preferably in the range of 1,000 to 1,000,000 U/mmol in case of CCL and in the range of 100 to 100,000 U/mmol in case of CALB. Even more preferably, said enzyme is present at an amount of about 60,000 U/mmol in case of CCL and about 5,000 U/mmol in case CALB.

Furthermore, from an economical/industrial point of view, the possibility to reutilize such enzymes in several cycles without losing the catalytic activity was proved.

The concentration of the initial diesters of formula II is preferably in the range of about 0.01 to 0.15 molar, more preferably about 0.025 molar.

The process of the invention preferably occurs in the presence of an organic solvent, more preferably an aprotic organic solvent.

Said solvent is then preferably selected from among toluene, acetonitrile, tetrahydrofuran, dichloromethane and/or chloroform.

The R'OH alcohol according to the invention is preferably selected from among methanol, ethanol, butanol and/or octanol.

Said alcohol is preferably present at a quantity in the range of about 0.5 to about 50 moles per mole of initial substrate, more preferably 5 moles per mole of substrate.

The process according to the present invention preferably occurs under constant stirring until the initial diester of formula II is dissolved. Subsequently the enzyme used is removed for filtration, preferably filtration on Celite and the monoester of formula I is obtained through evaporation of the solvent under low pressure.

When the compound of formula II is a 17 $\alpha$ ,21-diesters of cortexolone, the reaction time of the process is usually in the range of 20 to 150 hours, preferably in the range of 24 to 72

hours and the reaction temperature is preferably in the range of about 10 to 48° C., more preferably in the range of 20 to 32° C.

Table I below summarizes the reaction conditions and the results of the enzymatic alcoholysis according to the present invention.

TABLE 1

Enzymatic alcoholysis reaction of 17 $\alpha$ ,21-diester of cortexolone to produce the corresponding 17 $\alpha$ -monoester.					
Compound of formula II (diester)	Enzyme	Alcohol	Solvent	Reaction time (hours)	Yield of the monoester of formula I*
Diacetate	CCL	Octanol	Toluene	51	97%
	CALB	Ethanol	Toluene	96	67%
	CALB	Octanol	Acetonitrile	51	88%
	CCL	Ethanol	Toluene	120	73%
	CCL	Butanol	Toluene	24	100%
	CCL	Octanol	Toluene	28	100%
	CCL	Butanol	Acetonitrile	96	91%
	CCL	Butanol	Tetrahydrofuran	96	86%
	CCL	Butanol	Chloroform	96	10%
	PPL	Octanol	Toluene	120	13%
Dipropionate	PFL	Methanol	Chloroform	74	0%
	CALB	Octanol	Acetonitrile	76	91%
	CCL	Toluene	Butanol	74	98%
	CCL	Toluene	Octanol	24	98%
	Divalerate	Toluene	Butanol	74	81%
	CCL	Toluene	Octanol	48%	97%

\*the conversion percentages were evaluated from the  $^1\text{H-NMR}$  spectra from the integrations of signals due to the hydrogens in position 21 of the corresponding diesters and monoesters.

The enzymatic method according to the present invention also proved useful not only for converting 17 $\alpha$ -21-diesters of cortexolone or of 9,11-dehydro-cortexolone: in particular the 17 $\alpha$ -butanoate of 9,11-dehydrocortexolone was obtained starting from the corresponding dibutanoate preferably using the CCL enzyme and methanol as an acceptor alcohol of the acyl group.

The concentration of the initial 9,11-dehydro derivatives is preferably in the range of 0.01 to 0.15 molar, more preferably 0.025 molar.

In this case, the reaction time is preferably in the range of 45 to 55 hours, preferably 53 hours.

Also in this case the reaction temperature is preferably in the range of 10 to 48° C., more preferably in the range of 20 to 32° C.

Table 2 below shows the reaction conditions of the enzymatic alcoholysis of 17 $\alpha$ ,21-dibutanoate of 9,11-dehydrocortexolone and the related final yield of the respective monoester.

TABLE 2

Enzymatic alcoholysis reaction of 17 $\alpha$ ,21-diester of 9,11-dehydro-cortexolone to produce the corresponding 17 $\alpha$ -monoester.					
Compound of formula II (diester)	Enzyme	Alcohol	Solvent	Reaction time (hours)	Yield in compound of formula I*
Dibutanoate	CCL	Methanol	Toluene	53	79%
Dibutanoate	CCL	Ethanol	Toluene	53	28%
Dibutanoate	CCL	Butanol	Toluene	53	100%
Dibutanoate	CCL	Octanol	Toluene	53	100%

\*the conversion percentages were evaluated from the  $^1\text{H-NMR}$  spectra from the integrations of signals due to the hydrogens in position 21 of the corresponding diesters and monoesters

Furthermore, the process according to the present invention may optionally comprise a final step of crystallization from an organic solvent, water, buffered aqueous solutions and/or their mixture.

The organic solvent of said step of crystallization is preferably selected from among diisopropylether, tert-butylmethylether, dichloromethane, ethyl acetate, hexane, acetone, ethanol, water or their mixture at any proportion.

Thus, further object of the present invention are crystalline forms of 17 $\alpha$ -monoesters of cortexolone, and their corresponding 9,11-dehydro derivatives.

In particular, an object of the present invention are the crystalline forms of cortexolone 17 $\alpha$ -propionate and of 9,11-cortexolone-17 $\alpha$ -butanoate.

The crystalline form I of 17 $\alpha$ -propionate is preferably obtained through crystallization from tert-butylmethylether. The concentration of 17 $\alpha$ -propionate in said solvent is in the range of 0.9 to 1.1 g in 9-11 ml of tert-butylmethylether preferably 1 g in 10 ml. Said crystalline form I is characterized by a melting point in the range of about 133 to 135° C. and/or a DRX as in FIG. 1 and/or a DSC as shown in FIG. 2 and/or an IR as shown in FIG. 3.

The crystalline form II of 17 $\alpha$ -propionate is preferably obtained through crystallization from diisopropylether. The concentration in said solvent is preferably in the range of 0.9 to 1.1 g in 54-66 ml of diisopropylether.

Said crystalline form II is characterized by a melting point in the range of about 114 to 116° C. and/or a DRX as in FIG. 4 and/or a DSC as shown in FIG. 5 and/or an IR as shown in FIG. 6.

The crystalline form III of 17 $\alpha$ -propionate is preferably obtained through crystallization from a mixture of dichloromethane/n-hexane preferably in a ratio of about 1/30, acetone/n-hexane preferably in a ratio of about 1/8, or ethanol/water mixture preferably in a ratio of about 1/2.

The melting point of said crystalline forms III could not be determined.

The crystalline form III obtained from dichloromethane/n-hexane has a DRX as shown in FIG. 7 and/or a DSC as shown in FIG. 8 and/or an IR as shown in FIG. 9. The crystalline form III obtained from acetone/n-hexane has a DRX as shown in FIG. 10 and/or a DSC as shown in FIG. 11 and/or an IR as shown in FIG. 12.

The crystalline form III obtained from ethanol/water has a DRX as shown in FIG. 13 and/or a DSC as shown in FIG. 14 and/or an IR as shown in FIG. 15.

The crystalline form I of 9,11-dehydro-17 $\alpha$ -cortexolone is preferably obtained from tert-butylmethylether, diisopropylether, a dichloromethane/n-hexane mixture preferably in a ratio of 1/15, or an acetone/n-hexane mixture preferably in a ratio of 1/5.

The crystalline form I obtained from tert-butylmethylether has a DRX as shown in FIG. 16 and/or a DSC as shown in FIG. 17 and/or an IR as shown in FIG. 18.

The crystalline form I obtained from diisopropylether has a DRX as shown in FIG. 19 and/or a DSC as shown in FIG. 20 and/or an IR as shown in FIG. 21.

The crystalline form I obtained from dichloromethane/n-hexane has a DRX as shown in FIG. 22 and/or a DSC as shown in FIG. 23 and/or an IR as shown in FIG. 24.

The crystalline form I obtained from acetone/n-hexane has a DRX as shown in FIG. 25 and/or a DSC as shown in FIG. 26 and/or an IR as shown in FIG. 27.

The differences observable in the DRX diagrams regarding the form III of 17 $\alpha$ -propionate and regarding the form I of 9,11-dehydro derivative are to be deemed irrelevant in that they are due to the phenomena of crystal disorientation. Likewise, the differences observed in IR and DSC are to be deemed irrelevant in that they are due to variations when preparing the sample and/or when performing the analysis.

Table 3 shows some identification parameters and conditions for obtaining the abovementioned crystalline forms.

TABLE 3

Compound of formula I (monoester)	Solid form	Solvents	Concentrations (g compound/ ml solvent)	Melting point (° C.)	DRX	DSC	IR
Cortexolone 17 $\alpha$ - propionate	Crystalline form I	Tert- butylmethylether	1 g/10 ml	133-135	FIG. 1	134.90° C. ( $\Delta H = 40.68$ J/g) FIG. 2	FIG. 3
	Crystalline form II	diisopropylether	1 g/60 ml	114-116	FIG. 4	11585° C. ( $\Delta H = 46.61$ J/g) FIG. 5	FIG. 6
	Crystalline form III	dichloromethane/ n-hexane	1 g/15.51 ml (dichloromethane/ n-hexane 1/30)	n.d.	FIG. 7	134.90° C. ( $\Delta H = 42.45$ J/g) FIG. 8	FIG. 9
	Crystalline form III	Acetone/ n-hexane	1 g/9 ml (acetone/ n-hexane 1/8)	n.d.	FIG. 10	134.18° C. ( $\Delta H = 43.83$ J/g) FIG. 11	FIG. 12
9,11- dehydro 17 $\alpha$ - cortexolone	Crystalline form III	Ethanol/water	1 g/24 ml (ethanol/ water 1/2)	n.d.	FIG. 13	134.29° C. ( $\Delta H = 43.34$ J/g) FIG. 14	FIG. 15
	Crystalline form I	Tert- butylmethylether	1 g/24 ml	n.d.	FIG. 16	137.45° C. ( $\Delta H = 62.63$ J/g) FIG. 17	FIG. 18
	Crystalline form I	diisopropylether	1 g/96 ml	136	FIG. 19	136.76° C. ( $\Delta H = 60.48$ J/g) FIG. 20	FIG. 21

TABLE 3-continued

Compound of formula I (monoester)	Solid form	Solvents	Concentrations (g compound/ ml solvent)	Melting point (° C.)	DRX	DSC	IR
Crystalline form I	Dichloromethane/ n-hexane	1 g/16 ml (dichloromethane/ n-hexane 1/15)	n.d.	FIG. 22	136.65° C. (ΔH = 66.66 J/g) FIG. 23	FIG. 24	
Crystalline form I	Acetone/ n-hexane	1 g/21 ml (acetone/ n-hexane 1/5)	n.d.	FIG. 25	136.49° C. (ΔH = 67.64 J/g) FIG. 26	FIG. 27	

The existence of a pseudo polymorph crystalline form of 17 $\alpha$ -propionate, characterized by the presence of a crystallization water molecule and defined as solvate form IV was determined.

The solvate crystalline form IV of 17 $\alpha$ -propionate is preferably obtained through crystallization from an organic/water solvent mixture in a ratio generally in the range of 1/2 to 2/1, preferably from propylene glycol/water in a ratio of 1/1 or polyethyleneglycol/water in a ratio of 1/1.

The crystallization of 17 $\alpha$ -propionate in solvate form may occur during the formulation processes of the final pharmaceutical form, where the manufacturing process of the pharmaceutical form provides for the dissolution of the active ingredient in an organic solvent, such as for example, propylene glycol, polyethylene glycol or short-chained aliphatic alcohols, followed by the addition of water in a ratio of 1/3 to 3/1 with respect to the organic solvents used for the dissolution of the active ingredient.

Furthermore, an object of the present invention is a pharmaceutical composition containing at least one of the crystalline forms described above in association with at least one physiologically acceptable excipient.

The compositions of the present invention can be of solid, semi-solid, pasty or liquid form and they are preferably selected from among tablets, capsules, powders, pellets, suspensions, emulsions, solutions, creams, gel, ointment, lotions or pastes both ready to use or to be reconstituted before use.

Lastly, object of the present invention is the use, preferably for human beings, of at least one of the crystalline forms and/or solvates described above for the preparation of a medication for treating pathologies affecting the urogenital system, the endocrine system, the skin and/or the cutaneous appendages.

In particular, an object of the present invention is the use of a liquid or semi-liquid formulation for topical administration, such as for example, cream, gel, ointment, emulsion or dispersion containing cortexolone-17 $\alpha$ -propionate in the range of 0.1 to 2% by weight, preferably in the range of 0.2 to 1%, in a crystalline form selected from among solvate forms I, II, III or IV, preferably in solvate form IV, both in solution and crystalline dispersion states, the latter being possibly obtained also in an extemporaneous manner by precipitation of the crystalline active ingredient upon addition of water or aqueous solution to a solution containing the same active ingredient in an organic solvent or a mixture of organic solvents, for the preparation of a medication for treating pathologies affecting the urogenital system, the endocrine system, the skin and/or or skin appendages.

Additionally, an object of the present invention is the use of a liquid or solid formulation for oral or systemic administration, such as for example, a tablet, capsule, granule or powder containing 9,11-dehydro-cortexolone-17 $\alpha$ -butano-

ate in the dosage in the range of 4 to 65% by weight, preferably in the range of 5 to 50%, with respect to the total formulation when said total formulation has a final weight of 200 mg or in the range of 1 to 25% by weight, preferably in the range of 2 to 20%, when the total formulation has a final weight of 500 mg in a crystalline form selected between solvate forms I, or IV, for treating pathologies affecting the urogenital system, the endocrine system, the skin and/or or skin appendages.

Said pathologies according to the invention are preferably selected from among acne, seborrhoeic dermatitis, androgenetic alopecia, hirsutism, benign prostatic hyperplasia, forms of prostate cancer, male contraception, polycystic ovary syndrome, control of aggressive or aberrant sexual behaviors and syndrome of precocious puberty.

The following examples are included to enhance the understanding of the present invention without restricting it in any way whatsoever.

## EXAMPLES

### Example 1

#### Alcoholysis with CCL of Cortexolone 17 $\alpha$ , 21-Dipropionate

Add butanol (0.4 g, 5.45 mmoles) and CCL (17.4 g, 3.86 U/mg, FLUKA) to a solution of cortexolone-17 $\alpha$ ,21-dipropionate (0.5 g, 1.09 mmoles) in toluene (50 ml). Maintain the mixture under stirring, at 30° C., following the progress of the reaction in TLC (Toluene/ethyl acetate ¾) until the initial material is dissolved (24 h). Remove the enzyme by means of filtration using a Celite layer. Recover the cortexolone 17 $\alpha$ -propionate (0.437, 99%) after evaporation under low pressure. Through crystallization from diisopropyl ether you obtain a product with a purity >99% in HPLC.

<sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>) relevant signals δ (ppm) 5.78 (br s, 1H, H-4), 4.32 (dd, 1H, H-21), 4.25 (dd, 1H, H-21), 1.22 (s, 3H, CH<sub>3</sub>-19), 1.17 (t, 3H, CH<sub>3</sub>), 0.72 (s, 3H, CH<sub>3</sub>-18). P.f. 114° C.

### Example 2

According to the method described in example 1 prepare cortexolone-17 $\alpha$ -butanoate.

<sup>1</sup>H-NMR relevant signals δ (ppm) 5.78 (br s, 1H, H-4), 4.32 (dd, 1H, H-21), 4.26 (dd, 1H, H-21), 1.23 (s, 3H, CH<sub>3</sub>-19), 0.97 (t, 3H, CH<sub>3</sub>), 0.73 (s, 3H, CH<sub>3</sub>-18). P.F. 134-136° C.

**11**

## Example 3

According to the method described in the example prepare cortexolone-17 $\alpha$ -valerate.

<sup>1</sup>H-NMR relevant signals  $\delta$  (ppm) 5.77 (br s, 1H, H-4), 4.32 (dd, 1H, H-21), 4.26 (dd, 1H, H-21), 1.22 (s, 3H, CH<sub>3</sub>-19), 0.95 (t, 3H, CH<sub>3</sub>), 0.72 (s, 3H, CH<sub>3</sub>-18). P.f 114° C. (diisopropyl ether).

## Example 4

According to the method described in the example prepare 9,11-dehydro-cortexolone-17 $\alpha$ -butanoate.

<sup>1</sup>H-NMR relevant signals  $\delta$  (ppm) 5.77 (br s, 1H, H-4), 5.54 (m, 1H, H-9), 4.29 (dd, 1H, H-21), 4.24 (dd, 1H, H-21), 1.32 (s, 3H, CH<sub>3</sub>-19), 0.94 (t, 3H, CH<sub>3</sub>), 0.68 (s, 3H, CH<sub>3</sub>-18). P.f 135-136° C. (acetone/hexane).

## Example 5

Alcoholysis with CALB of Cortexolone-17 $\alpha$ ,21-Dipropionate

Dissolve cortexolone, 17 $\alpha$ , 2-dipropionate (0.5 g, 1.09 mmoles) in acetonitrile (40 ml), add CALB (2.3 g, 2.5 U/mg Fluka) and octanol (0.875 ml). Leave the mixture under stirring, at 30° C., for 76 hrs. Remove the enzyme by means of filtration using a paper filter. Once the solvents evaporate, recover a solid (0.4758) which upon analysis <sup>1</sup>H-NMR shall appear made up of cortexolone-17 $\alpha$ -propionate at 91%.

## Example 6

## Crystallization

Add the solvent (t-butylmethylether or diisopropylether) to the sample according to the ratios indicated in Table 3. Heat the mixture to the boiling temperature of the solvent, under stirring, until the sample dissolves completely. Cool to room temperature and leave it at this temperature, under stirring, for 6 hours. Filter using a buchner funnel and maintain the solid obtained, under low pressure, at a room temperature for 15 hours and then, at 40° C., for 5 hours.

## Example 7

## Precipitation

Dissolve the sample in the suitable solvent (dichloromethane, acetone, ethyl acetate or ethanol) according to the ratios indicated in table 3 and then add the solvent, hexane or water, according to the ratios indicated in table 3, maintaining the mixture, under stirring, at room temperature. Recover the precipitate by filtration using a buchner funnel and desiccate as in example 6.

## Example 8

## Obtaining a pharmaceutical form containing the medication in a defined crystalline form.

Prepare a fluid cream containing 2% cetyllic alcohol, 16% glyceryl monostearate, 10% vaseline oil, 13% propylene glycol, 10% polyethyleneglycol with low polymerization 1.5% polysorbate 80 and 47.5% purified water. Add 1 g of cortexolone 17 $\alpha$ -propionate of crystalline form III to 100 g of this cream and subject the mixture to homogenization by means of a turbine agitator until you obtain homogeneity. You obtain a cream containing a fraction of an active ingredient dissolved in the formulation vehicle and a non-dissolved fraction of an active ingredient, present as a crystal

**12**

of crystalline form III. This preparation is suitable for use as a formulation vehicle for skin penetration tests on Franz cells, where a coefficient of penetration in the range of 0.04 to 0.03 cm/h is observed on the preparation.

## Example 9

## Obtaining the Pharmaceutical Form Containing the Medication in Solvate Form IV for Replacing the Solvent During the Galenic Formulation Procedure

Dissolve 100 g of cortexolone 17 $\alpha$ -propionate of crystalline form III in 2500 g of propylene glycol under stirring at room temperature. Separately prepare, by using a turbomeulsifier raising the temperature up to about 70° C., an emulsion with 250 g of Cetyllic alcohol, 1500 g of glyceryl monostearate, 1000 g of liquid paraffin, 5 g of mixed tocopherols, 100 g of polysorbate 80 and 4650 g of water. After cooling the emulsion up to about 30° C., add—under stirring and under negative pressure—the cortexolone 17 $\alpha$ -propionate solution in propylene glycol. Maintain the emulsified cream under stifling until you obtain homogeneity, making sure the temperature remains low by means the circulation of a coolant.

The cream contains a dispersed crystalline fraction, made up of an active ingredient in solvate crystalline form IV, formed due to the precipitation of the active ingredient itself from the glycolic solution which contained it when the latter was added to the predominantly aqueous formulation. The DRX spectra of the crystalline form present in the cream are indicated in FIG. 28.

What is claimed is:

1. A composition comprising:
  - a) crystalline form III of cortexolone-17 $\alpha$ -propionate characterized by a DRX spectrum as represented in FIG. 7, 10, or 13, or a DRX spectrum with at least peaks at about: 6.2, 12.6, 14.1, 14.3, 16.0, 22.4, and 23.7 degrees 2theta, or a DSC spectrum as represented in FIG. 8, 11, or 14, or an IR spectrum as shown in FIG. 9, 12, or 15; and
  - b) crystalline form IV of cortexolone-17 $\alpha$ -propionate characterized by a DRX spectrum as represented in FIG. 28, or a DRX spectrum with at least peaks at about: 4.8, 12.9, 14.4, 15.8, 16, 19.3, and 19.5 degrees 2theta.
2. The composition of claim 1, further comprising at least one physiologically acceptable excipient.
3. The composition of claim 2, wherein the at least one physiologically acceptable excipient is propylene glycol, cetyllic alcohol, glyceryl monostearate, liquid paraffin, or a combination of any of the foregoing.
4. The composition of claim 2, further comprising mixed tocopherols, polysorbate 80, or a combination thereof.
5. The composition of claim 2, wherein the composition is in the form of a tablet, capsule, powder, pellet, suspension, emulsion, cream, gel, ointment, lotion, or paste.
6. The composition of claim 2, wherein the composition is in the form of a solid, semi-solid, or a paste.
7. The composition of claim 5, wherein the composition is in the form of a cream.
8. The composition of claim 7, wherein the composition further comprises solubilized cortexolone-17 $\alpha$ -propionate.
9. The composition of claim 8, wherein the solubilized cortexolone-17 $\alpha$ -propionate is present in the composition in a concentration of from 0.1 to 2% by weight of the composition.
10. The composition of claim 8, wherein the solubilized cortexolone-17 $\alpha$ -propionate, crystalline form III of cortex-

**13**

olone-17 $\alpha$ -propionate, and crystalline form IV of cortexolone-17 $\alpha$ -propionate together comprise 0.1 to 2% by weight of the composition or comprise 0.2 to 1% by weight of the composition.

**11.** A method of treating a pathology affecting the skin and/or the cutaneous appendages, wherein the pathology affecting the skin and/or the cutaneous appendages is acne, androgenetic alopecia, hirsutism, or seborrheic dermatitis, the method comprising administering to a subject in need thereof an effective amount of a composition comprising

- <sup>10</sup> a) crystalline form III of cortexolone-17 $\alpha$ -propionate characterized by a DRX spectrum as represented in FIG. 7, 10, or 13, or a DRX spectrum with at least peaks at about: 6.2, 12.6, 14.1, 14.3, 16.0, 22.4, and 23.7 degrees 2theta, or a DSC spectrum as represented in FIG. 8, 11, or 14, or an IR spectrum as shown in FIG. 9, 12, or 15; and;
- b) crystalline form IV of cortexolone-17 $\alpha$ -propionate characterized by a DRX spectrum as represented in FIG. 28, or a DRX spectrum with at least peaks at about: 4.8, 12.9, 14.4, 15.8, 16, 19.3, and 19.5 degrees 2theta.

**12.** The method of claim **11**, wherein the administering comprises topically applying the composition.

**13.** The method of claim **12**, wherein the pathology affecting the skin and/or the cutaneous appendages is acne.

**14.** The method of claim **12**, wherein the pathology affecting the skin and/or the cutaneous appendages is androgenetic alopecia.

**15.** The method of claim **12**, wherein the pathology affecting the skin and/or the cutaneous appendages is hirsutism.

**14**

**16.** The method of claim **12**, wherein the pathology affecting the skin and/or the cutaneous appendages is seborrheic dermatitis.

**17.** A method of treating a pathology affecting the skin and/or the cutaneous appendages, wherein the pathology affecting the skin and/or the cutaneous appendages is acne, androgenetic alopecia, hirsutism, or seborrheic dermatitis, the method comprising administering to a subject in need thereof an effective amount of a composition comprising:

- a) water;
- b) at least one physiologically acceptable excipient;
- c) crystalline form III of cortexolone-17 $\alpha$ -propionate characterized by a DRX spectrum as represented in FIG. 7, 10, or 13, or a DRX spectrum with at least peaks at about: 6.2, 12.6, 14.1, 14.3, 16.0, 22.4, and 23.7 degrees 2theta, or a DSC spectrum as represented in FIG. 8, 11, or 14, or an IR spectrum as shown in FIG. 9, 12, or 15; and
- d) crystalline form IV of cortexolone-17 $\alpha$ -propionate characterized by a DRX spectrum as represented in FIG. 28, or a DRX spectrum with at least peaks at about: 4.8, 12.9, 14.4, 15.8, 16, 19.3, and 19.5 degrees 2theta.

**18.** The method of claim **17**, wherein the administering comprises topically applying the composition.

**19.** The method of claim **18**, wherein the pathology affecting the skin and/or the cutaneous appendages is acne.

**20.** The method of claim **18**, wherein the at least one physiologically acceptable excipient is propylene glycol, cetyl alcohol, glyceryl monostearate, liquid paraffin, or a combination of any of the foregoing.

\* \* \* \* \*